Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avotermin for Scar Improvement in Healthy Volunteers
NCT00627536Phase 2Completed
- Sponsor
- Renovo
- Start
- Jul 2006
- Primary completion
- Mar 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of avotermin in cicatrix (8 arms), sponsored by Renovo. Primary endpoint: Scar appearance at 7 months. Started Jul 2006; status: completed.
02
Drugs
avotermin
03
Conditions
cicatrix
Beyond the preview
Go deeper on NCT00627536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00627536.